Article
Clinical Neurology
Soonil Kwon, So-Ryoung Lee, Eue-Keun Choi, Euijae Lee, Jin-Hyung Jung, Kyung-Do Han, Myung-Jin Cha, Seil Oh, Gregory Y. H. Lip
Summary: This study compared the effectiveness and safety of NOACs and warfarin among atrial fibrillation patients with prior GIB using the Korean claims database. The findings showed that NOACs were associated with lower risks of ischemic stroke and major bleeding compared to warfarin in this patient population.
Article
Cardiac & Cardiovascular Systems
Amelie Gabet, Valerie Olie, Yannick Bejot
Summary: The prevalence of AF and use of OAC among patients with ICH increased over time. However, while premorbid use of OAC was highly associated with poor outcomes after ICH, AF itself was not significantly associated with outcomes in patients with ICH.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Clinical Neurology
Flurina Lyrer, Annaelle J. Zietz, David J. Seiffge, Masatoshi Koga, Bastian Volbers, Duncan Wilson, Bruno Bonetti, Sabine Schaedelin, Henrik Gensicke, Sohei Yoshimura, Kosmas Macha, Gareth Ambler, Sebastian Thilemann, Tolga Dittrich, Manabu Inoue, Kaori Miwa, Ruihao Wang, Gabriela Siedler, Luise M. Biburger, Martin M. H. Brown, Rolf H. Jager, Keith Muir, Christopher Traenka, Kanta Tanaka, Masayuki H. Shiozawa, Leo H. Bonati, Nils Peters, Gregory Y. H. A. Lip, Philippe A. Lyrer, Manuel Cappellari, Kazunori Toyoda, Bernd Kallmunzer, Stefan J. Schwab, David J. T. Werring, Stefan T. Engelter, Gian Marco A. De Marchis, Alexandros A. Polymeris
Summary: This study aimed to compare the risk of stroke recurrence between known atrial fibrillation before stroke (KAF) and atrial fibrillation detected after stroke (AFDAS) in patients with anticoagulation, and to investigate the impact of pre-existing anticoagulation on this risk difference. The study found that only pre-existing anticoagulation, not KAF, was independently associated with a higher risk of stroke recurrence. Therefore, future research should focus on the causes of stroke despite anticoagulation to develop improved preventive treatments.
ANNALS OF NEUROLOGY
(2023)
Article
Clinical Neurology
Takeshi Yoshimoto, Kazunori Toyoda, Masafumi Ihara, Hiroshi Inoue, Takeshi Yamashita, Shinya Suzuki, Masaharu Akao, Hirotsugu Atarashi, Takanori Ikeda, Ken Okumura, Yukihiro Koretsune, Wataru Shimizu, Hiroyuki Tsutsui, Atsushi Hirayama, Masahiro Yasaka, Hirofumi Maruyama, Satoshi Teramukai, Tetsuya Kimura, Yoshiyuki Morishima, Atsushi Takita, Takenori Yamaguchi
Summary: The history of stroke/TIA in elderly patients increases the risk of stroke, bleeding, and death. Among patients with prior ischemic stroke/TIA, taking direct oral anticoagulants reduces the risk of bleeding events.
Article
Oncology
Anne Gulbech Ording, Mette Sogaard, Flemming Skjoth, Erik Lerkevang Grove, Gregory Y. H. Lip, Torben Bjerregaard Larsen, Peter Bronnum Nielsen
Summary: The Danish nationwide cohort study found comparable 1-year bleeding risk associated with DOAC compared with VKA among patients with AF and GI cancer.
Article
Multidisciplinary Sciences
Rungroj Krittayaphong, Thanita Boonyapiphat, Suchart Aroonsiriwattana, Pornchai Ngamjanyaporn, Gregory Y. H. Lip
Summary: This study aimed to determine the causes of death in Asian non-valvular atrial fibrillation (AF) patients registered in a nationwide AF registry, and investigate the differences in causes of death between AF patients who were taking and not taking oral anticoagulant (OAC). The COOL-AF study in Thailand enrolled 3,405 non-valvular AF patients and found that non-cardiovascular death, such as infection/sepsis or malignancy, was more prevalent than cardiovascular death in Asian AF patients. Thus, an improved integrated care approach is needed to reduce non-cardiovascular death in Asian AF patients.
Review
Pharmacology & Pharmacy
Ines Antunes Neves, Andreia Magalhaes, Gustavo Lima da Silva, Ana G. Almeida, Margarida Borges, Joao Costa, Joaquim J. Ferreira, Fausto J. Pinto, Daniel Caldeira
Summary: Oral anticoagulation is effective in reducing the risk of thromboembolic events in POAF patients after cardiac surgery, but not in those after non-cardiac surgery. However, it is associated with an increased risk of bleeding in both settings.
VASCULAR PHARMACOLOGY
(2022)
Article
Clinical Neurology
Satoshi Suda, Yasuyuki Iguchi, Yoshiki Yagita, Takao Kanzawa, Seiji Okubo, Shigeru Fujimoto, Yu Kono, Kazumi Kimura
Summary: This study investigated the rate, timing, and safety of oral anticoagulant (OAC) resumption after intracerebral hemorrhage (ICH) in current clinical practice in Japan. The results showed that early resumption of OAC appeared to be safe for patients with non-valvular atrial fibrillation (NVAF) after ICH, and the timing of resumption was associated with functional outcomes at discharge.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Medicine, General & Internal
Urs Fischer, Masatoshi Koga, Daniel Strbian, Mattia Branca, Stefanie Abend, Sven Trelle, Maurizio Paciaroni, Goetz Thomalla, Patrik Michel, Krassen Nedeltchev, Leo H. Bonati, George Ntaios, Thomas Gattringer, Else-Charlotte Sandset, Peter Kelly, Robin Lemmens, P. N. Sylaja, Diana Aguiar de Sousa, Natan M. Bornstein, Zuzana Gdovinova, Takeshi Yoshimoto, Marjaana Tiainen, Helen Thomas, Manju Krishnan, Gek C. Shim, Christoph Gumbinger, Jochen Vehoff, Liqun Zhang, Kosuke Matsuzono, Espen Kristoffersen, Philippe Desfontaines, Peter Vanacker, Angelika Alonso, Yusuke Yakushiji, Caterina Kulyk, Dimitri Hemelsoet, Sven Poli, Ana Paiva Nunes, Nicoletta Caracciolo, Peter Slade, Jelle Demeestere, Alexander Salerno, Markus Kneihsl, Timo Kahles, Daria Giudici, Kanta Tanaka, Silja Raty, Rea Hidalgo, David J. Werring, Martina Goldlin, Marcel Arnold, Cecilia Ferrari, Seraina Beyeler, Christian Fung, Bruno J. Weder, Turgut Tatlisumak, Sabine Fenzl, Beata Rezny-Kasprzak, Arsany Hakim, Georgia Salanti, Claudio Bassetti, Jan Gralla, David J. Seiffge, Thomas Horvath, Jesse Dawson
Summary: This study aimed to compare the effect of early initiation versus later initiation of direct oral anticoagulants (DOACs) on acute ischemic stroke in patients with atrial fibrillation. The results showed that there was no significant difference in the incidence of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death within 30 days between early and later use of DOACs.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Emily P. Zeitler, Stephen Kearing, Megan Coylewright, Devi Nair, Jonathan C. Hsu, Douglas Darden, A. James O'Malley, Andrea M. Russo, Sana M. Al-Khatib
Summary: In a real-world population of older Medicare beneficiaries with atrial fibrillation, left atrial appendage occlusion (LAAO) was associated with a significant reduction in the risk of death and stroke among both women and men, compared with anticoagulation. The bleeding risk was higher in LAAO recipients shortly after the procedure but decreased after the 6-week periprocedural period. These findings should be taken into account in shared decision-making with patients considering strategies for reducing AF-related stroke.
Article
Geriatrics & Gerontology
Kuo-Hsuan Chang, Chiung-Mei Chen, Chun-Li Wang, Hui-Tzu Tu, Yu-Tung Huang, Hsiu-Chuan Wu, Chien-Hung Chang, Shang-Hung Chang
Summary: This retrospective cohort study examined the association between direct oral anticoagulants (DOACs) and concurrent antidepressant use in patients with atrial fibrillation (AF). The study found that concurrent use of bupropion with DOACs increased the risk of major bleeding and gastrointestinal hemorrhage. The combinations of DOACs with selective serotonin reuptake inhibitors (SSRIs) and tetracyclic antidepressants (TeCAs) were associated with an increased risk of intracerebral hemorrhage. The study suggests that careful consideration should be given to drug-drug interactions when prescribing DOACs to adult patients with AF.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Oncology
Sina Burth, Mona Ohmann, Dorothea Kronsteiner, Meinhard Kieser, Sarah Loew, Lars Riedemann, Mona Laible, Anne Berberich, Katharina Druschler, Timolaos Rizos, Antje Wick, Frank Winkler, Wolfgang Wick, Simon Nagel
Summary: During a follow-up of just under 9 months, anticoagulation did not appear to impact the incidence of intracranial hemorrhage in patients with glioblastoma or brain metastases.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Chun-Li Wang, Chien-Hao Huang, Victor Chien-Chia Wu, Ya-Chi Huang, Hsiang-Sheng Wang, Chang-Fu Kuo, Pao-Hsien Chu, Ming-Shien Wen, Ying-Jen Chen, Yu-Tung Huang, Shang-Hung Chang
Summary: In patients with atrial fibrillation, direct oral anticoagulants (DOACs) were found to be as effective as warfarin in preventing ischemic stroke/systemic embolism regardless of peptic ulcer status, and they were also safer in reducing major bleeding in patients without peptic ulcer. There were no significant differences in the effects of DOAC and warfarin on major bleeding or gastrointestinal bleeding in patients with active or inactive peptic ulcers.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Cardiac & Cardiovascular Systems
Huiya Cai, Guoquan Chen, Wei Hu, Chunjiao Jiang
Summary: In atrial fibrillation patients with prior intracranial haemorrhage, oral anticoagulation is associated with a reduced risk of ischemic stroke/systemic thromboembolism and all-cause death, without increasing intracranial haemorrhage recurrence, but may increase the risk of major bleeding. Non-vitamin K antagonist oral anticoagulants have a better safety profile and comparable efficacy compared to warfarin.
Article
Cardiac & Cardiovascular Systems
Xing Wang, Dingke Wen, Yuqi Chen, Chao You, Lu Ma
Summary: This study examined the effectiveness of different oral anticoagulation agents in patients with atrial fibrillation who survive an intracranial hemorrhage. The results showed that both DOAC and warfarin were superior to antiplatelet therapy or no therapy in preventing thromboembolic events. Furthermore, DOAC also showed superiority in preventing thromboembolic events, repeat ICH, and all-cause mortality compared to warfarin. Therefore, DOACs may be a reasonable alternative for patients with atrial fibrillation who experience ICH, although further validation through ongoing trials is needed.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2023)